Monashee Investment Management »

An2 Therapeutics shares owned by Monashee Investment Management

Quarter-by-quarter ownership of An2 Therapeutics (ANTX) shares owned by Monashee Investment Management from 13F filings

Historical chart of Monashee Investment Management investment in An2 Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including An2 Therapeutics held by Monashee Investment Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in An2 Therapeutics by Monashee Investment Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $697k 34k 20.49
2023-09-30 $1.6M 100k 16.08
2023-06-30 $1.5M 182k 8.50
2023-03-31 $2.4M 248k 9.87
2022-12-31 $4.3M 450k 9.53
2022-09-30 $4.1M 233k 17.38
2022-06-30 $1.8M 233k 7.75
2022-03-31 $6.5M 433k 15.07

More positions owned by Monashee Investment Management

Ishares Tr Core S&p500 Etf (IVV)
Vanguard Index Fds S&p 500 Etf Shs (VOO)
Vanguard Tax-managed Fds Van Ftse Dev Mkt (VEA)
Ishares Tr Core Msci Eafe (IEFA)
Vanguard Intl Equity Index F Ftse Emr Mkt Etf (VWO)
Ishares Core Msci Emkt (IEMG)
Ishares Tr Core S&p Ttl Stk (ITOT)
Vanguard Index Fds Total Stk Mkt (VTI)
Structure Therapeutics Sponsored Ads (GPCR)
Aercap Holdings Nv SHS (AER)
PG&E Corporation (PCG)
Korro Bio (KRRO)
Eyepoint Pharmaceuticals Com New (EYPT)
Celldex Therapeutics Com New (CLDX)
Roivant Sciences SHS (ROIV)

View all positions for Monashee Investment Management

Top funds holding An2 Therapeutics

RA Capital Management
BVF
Citadel Advisors
Frazier Life Sciences Management
Henderson Group
Avidity Partners Management
Vanguard Group
Octagon Capital Advisors
Marshall Wace
Nantahala Capital Management
T. Rowe Price Associates
Citigroup
Jane Street
Victory Capital Management
Alyeska Investment Group

View all funds holding An2 Therapeutics